In the last trading session, 15,812,495 Bionano Genomics, Inc. (NASDAQ:BNGO) shares changed hands as the company’s beta touched 0. With the company’s per share price at $7.22 changed hands at -$0.4 or -0.05% during last session, the market valuation stood at $2.01 Billion. BNGO’s last price was a discount, traded about -117.31% off its 52-week high of $15.69. The share price had its 52-week low at $0.43, which suggests the last value was 94.04% up since then. When we look at Bionano Genomics, Inc.’s average trading volume, we note the 10-day average is 16.5 Million shares, with the 3-month average coming to 23.88 Million.
Analysts gave the Bionano Genomics, Inc. (BNGO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.2. If we narrow down to specifics, the data shows that none out of 4 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended BNGO as a Hold, 4 felt it is a Buy and none rated the stock as Underweight. Bionano Genomics, Inc.’s EPS for the current quarter is expected to be -$0.04.
Bionano Genomics, Inc. (NASDAQ:BNGO) trade information
Although BNGO has turned red as seen at the end of in last trading. With action -5.25%, the performance over the past five days has been red. The jump to weekly highs of $8.12- on Thursday, Jun 17 added 11.08% to the stock’s daily price. The company’s shares are showing year-to-date upside of 1.34%, with the 5-day performance at -0.08% in the red. However, in the 30-day time frame, Bionano Genomics, Inc. (NASDAQ:BNGO) is 0.31% up. Looking at the short shares, we see there were 38.52 Million shares sold at short interest cover period of 1.61 days.
The consensus price target for the stock as assigned by Wall Street analysts is $11.5, meaning bulls need an upside of 59.28% from its current market value. According to analyst projections, BNGO’s forecast low is $10 with $14 as the target high. To hit the forecast high, the stock’s price needs a +93.91% upsurge from its current level, while the stock would need to tank 38.5% for it to hit the projected low.
Bionano Genomics, Inc. (BNGO) estimates and forecasts
Data shows that the Bionano Genomics, Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot +1257.14% over the past 6 months, a 51.28% in annual growth rate that is considerably higher than the industry average of 9.1%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Bionano Genomics, Inc. will rise +55.6%, while the growth in revenue is estimated to hit 37.5% for the next quarter. Year-over-year growth is forecast to reach 88.8% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of $3.52 Million. 4 analysts are of the opinion that Bionano Genomics, Inc.’s revenue for the quarter ending September 01, 2021 will be $4.2 Million. The company’s revenue for the corresponding quarters a year ago was $1.18 Million and $2.2 Million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 197.8%. The estimates for the next quarter sales put growth at 91.3%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0%. The 2021 estimates are for Bionano Genomics, Inc. earnings to increase by 80.2%, but the outlook for the next 5-year period is at 0% per year.
Bionano Genomics, Inc. (NASDAQ:BNGO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.34% of Bionano Genomics, Inc. shares while 15.86% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 15.91%. There are 144 institutions holding the Bionano Genomics, Inc. stock share, with Renaissance Technologies, LLC the top institutional holder. As of Mar 30, 2021, the company held 3.4% of the shares, roughly 9.49 Million BNGO shares worth $76.65 Million.
Vanguard Group, Inc. (The) holds the second largest percentage of outstanding shares, with 3.33% or 9.3 Million shares worth $75.11 Million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Vanguard Total Stock Market Index Fund and Invesco ETF Tr-Invesco DWA Healthcare Momentum ETF. With 6187346 shares estimated at $49.99 Million under it, the former controlled 2.22% of total outstanding shares. On the other hand, Invesco ETF Tr-Invesco DWA Healthcare Momentum ETF held about 1.13% of the shares, roughly 3.15 Million shares worth around $19.46 Million.